The embodiments disclosed herein relate to medical devices for use in adjoining bone fragments, and more particularly to conformable bone plates for repair of craniomaxillofacial bony defects and methods of using conformable bone plates.
Maxillofacial and craniofacial injuries encompass any injury to the mouth, face and jaw. Common serious injury to the face occurs when bones are broken (a fracture). Fractures can involve the lower jaw, upper jaw, palate, cheekbones, eye sockets and combinations of these bones. The fracture needs to be held in the correct position while the bone is healing. In most cases this requires fixing the bones using metal or biodegradable plates and screws, known as internal fixation.
There are a variety of micro, mini and reconstruction plating systems. One of the most commonly used plating system developed to date is the Luhr system manufactured by Howmedica, Inc. Subsequently, based on the original concept by Luhr, several complete systems have been developed for use in all the various situations encountered in trauma and reconstructive surgery of the facial skeleton. Techniques and materials used for the internal fixation of the maxillofacial skeleton continue to evolve and improve. For example, metal plates have been used for the repair of craniomaxillofacial bone fractures. These metal plates are generally secured to the fractured bone portions with fasteners such as screws. The plates conventionally employed generally comprise small, generally flat, elongated sections of metal. The sections contain round screw holes at various points along their lengths for fastening the sections to bone. The metal plate is then bent into shape and secured to the fractured bone using a plurality of fasteners seated within the screw holes. While known systems utilizing plates and fasteners for aiding the osteosynthesis of severed bone regions have proven to be acceptable for certain applications, such systems are nevertheless susceptible to improvements that may enhance their performance. For example, metals are difficult to shape and are hampered by disadvantages such as infection and corrosion. Several resorbable plate and screw fixation systems are now available for use in the maxillofacial skeleton. These systems allow initial stable fixation of bone segments during the bone-healing phase and then gradually are reabsorbed through physiologic processes.
Regardless of the plate system used, the plate must be contoured to lay passively against the underlying bone surfaces. Therefore, even though the plating systems themselves are manufactured with extremely precise tolerances, an element of imprecision remains for surgeons who repair facial fractures and do orthognathic surgery or reconstructive procedures repositioning the facial skeletal structures to improve esthetics or function. When an osteotomy, fracture, or bone graft is placed into appropriate position, the bone plate has to be manually bent to the contour of the anatomy. This manual manipulation creates a substantial element of imprecision even with the use of templates. Maladapted bone plates lead to inappropriate bone contour, irritation of the overlying soft tissues, abnormal anatomy or contour defects and either non-union, malunion or unaesthetic results.
Thus, there is a need in the art for devices and methods for repairing maxillofacial and craniofacial bony defects that are easy to use, biocompatible, require minimal manipulation once in place, and are customizable on a patient-by-patient basis.
Conformable bone plates and methods for using the bone plates to adjoin bone fragments are disclosed herein. According to aspects illustrated herein, there is provided a bone plate for adjoining at least two bone fragments that includes a flexible pad capable of expanding, the pad having a first surface and a second surface; and at least one aperture for receiving a fastener, the at least one aperture extending from the first surface to the second surface, wherein the bone plate is able to move from a first compact position to a second expanded position and is contoured to passively engage against the at least two bone fragments.
According to aspects illustrated herein, there is provided a device for adjoining at least two bone fragments that includes a delivery catheter having an elongated shaft with a proximal end, a distal end, and a longitudinal axis therebetween, wherein the delivery catheter has an inner void for passage of at least one filling material and an inner lumen for passage of light from a light source; a conformable bone plate releasably engaging the distal end of the delivery catheter, wherein the conformable bone plate has a first surface, a second surface, a proximal end, and a distal end and at least one aperture extending from the first surface to the second surface for receiving a fastener; and an adapter releasably engaging the proximal end of the delivery catheter for receiving light from the light source and a delivery system housing the at least one filling material.
According to aspects illustrated herein, there is provided a method for adjoining at least two bone fragments that includes providing a device for adjoining at least two bone fragments, the device including a conformable bone plate engaged to a delivery catheter having an elongated shaft with a proximal end, a distal end, and a longitudinal axis therebetween, wherein the conformable bone plate has at least one aperture extending from a first surface of the bone plate to a second surface of the bone plate for receiving a fastener to affix the bone plate to the at least two bone fragments; positioning the conformable bone plate over an exterior surface spanning the at least two bone fragments; attaching a delivery system housing at least one filling material to the delivery catheter, wherein the elongated shaft of the delivery catheter has an inner void for passage of the at least one filling material to the conformable bone plate; inserting a light source into the delivery catheter, wherein the elongated shaft of the delivery catheter has an inner lumen for passage of the light source to the conformable bone plate; infusing the at least one filling material through the elongated shaft of the delivery catheter and into the conformable bone plate to expand the conformable bone plate; activating the light source to harden the at least one filling material in the expanded conformable bone plate; releasing the hardened conformable bone plate from the delivery catheter; and affixing the conformable bone plate to the exterior surfaces of the at least two bone fragments to adjoin the bone fragments.
The presently disclosed embodiments will be further explained with reference to the attached drawings, wherein like structures are referred to by like numerals throughout the several views. The drawings shown are not necessarily to scale, with emphasis instead generally being placed upon illustrating the principles of the presently disclosed embodiments.
While the above-identified drawings set forth presently disclosed embodiments, other embodiments are also contemplated, as noted in the discussion. This disclosure presents illustrative embodiments by way of representation and not limitation. Numerous other modifications and embodiments may be devised by those skilled in the art which fall within the scope and spirit of the principles of the presently disclosed embodiments.
Medical devices and methods for repairing maxillofacial and craniofacial injuries are disclosed herein. The craniomaxillofacial bone plates of the presently disclosed embodiments are made from a pliable, resilient, conformable, biocompatible, and strong material. At least one filling material is contained within the bone plates of the presently disclosed embodiments. During a procedure for repairing a craniomaxillofacial injury, a conformable bone plate is brought to the site of injury (an osteotomy, a fracture, a bone graft or other site of injury) in a deflated state. Once in place, the bone plate is expanded from a deflated state to an inflated state in situ by the addition of the at least one filling material. The addition of the at least one filling material may be precisely controlled such that the bone plate will resemble the contour of the site, on a patient-by-patient basis. Once the desired level of expansion is achieved, the at least one filling material is hardened within the bone plate using a light source. The hardened bone plate is then affixed to the site using fasteners. The customizable bone plate of the presently disclosed embodiments provides support and proper orientation of the bony defect resulting in the repair, healing, and strengthening of the defect.
Filling materials include, but are not limited to, bone reinforcing mixtures (such as bone cement mixtures, bone void fillers, epoxies, glues and similar adhesives), orthopedic wires, stainless-steel rods, metal pins, and other similar devices. The filling material may be a natural or synthetic material for strengthening, replacing, or reinforcing of bones or bone tissue. Bone reinforcing mixtures include glues, epoxies, adhesives, cements, hard tissue replacement polymers, biodegradable polymers such as PLA, PGA, and PLA-PGA copolymers, natural coral, hydroxyapatite, beta-tricalcium phosphate, and various other biomaterials known in the art for strengthening, replacing or reinforcing bones. As inert materials, bone reinforcing mixtures may be incorporated into surrounding tissue or gradually replaced by original tissue. Those skilled in the art will recognize that numerous bone reinforcing mixtures known in the art are within the spirit and scope of the presently disclosed embodiments.
A device disclosed herein may be used for the repair of a craniomaxillofacial bony defect related to trauma, tumors, as well as for developmental and congenital craniomaxillofacial deformities.
The main components of a device for repairing a craniomaxillofacial bony defect are shown generally in
A stiffening member 105 may surround the elongated shaft of the delivery catheter 110 and provides rigidity over the elongated shaft. A pusher or stabilizer 116 is loaded proximal to the bone plate 103. A slip sleeve 107 may surround the stiffening member 105. In an embodiment, the slip sleeve 107 surrounds the stiffening member 105 from a proximal end 123 of the bone plate 103 up until the pusher 116. One or more radiopaque markers or bands 130 may be placed at various locations along the bone plate 103 and/or the slip sleeve 107 for alignment of the device 100 during fluoroscopy or other forms of visualization. The one or more radiopaque bands 130, using radiopaque materials such as barium sulfate, tantalum, or other materials known to increase radiopacity, allows a medical professional to view the device 100 using fluoroscopy techniques. The one or more radiopaque bands 130 also provide visibility during inflation of the bone plate 103 to determine the precise positioning of the bone plate 103 and the device 100 during placement and inflation. The one or more radiopaque bands 130 permit visualization of any voids that may be created by air that gets entrapped in the bone plate 103. The one or more radiopaque bands 130 permit visualization to preclude the bone plate 103 from misengaging or not meeting the bony defects due to improper inflation. It may be desirable to imbed radiopaque beads on the corners of the conformable bone plate 103 to assist in the visualization/location of the bone plate 103.
In an embodiment, an adapter 115, such as a Tuohy-Borst adapter, engages the proximal end 102 of the delivery catheter 110. A light source that includes a light pipe 152 may be introduced into one of the side-arms of the adapter 115 and passes within an inner lumen of the delivery catheter 110 up until the distal end 104 of the delivery catheter 110. A delivery system 160 housing the filling material may be introduced into another side-arm of the adapter 115, as shown in
Examples of delivery systems include, but are not limited to, caulking gun type systems, syringe systems, bag systems that contain the filling material where the delivery of the filling material is controlled using a tube clamp or any other restrictor valve. In the embodiments shown in
In an embodiment, the syringe 160 is opaque and does not allow light to penetrate within the syringe 160. Having an opaque syringe 160 ensures that the filling material contained in the syringe 160 is not exposed to light and will not cure in the syringe 160. The filling material is of a liquid consistency, as measured in Centipoise (cP), the unit of dynamic viscosity, so the filling material may be infused from the syringe 160 into the delivery catheter 110 and into the bone plate 103. Because the filling material has a liquid consistency and is viscous, the filling material may be delivered using low pressure delivery and high pressure delivery is not required, but may be used.
In an embodiment, a separation area is located at the junction between the proximal end 123 of the bone plate 103 and the delivery catheter 110. The separation area may also include an illumination band. When activated, the illumination band causes light to cure the filling material located in the bone plate 103 within the illumination band. The illumination band extends around the delivery catheter 110 and has a stress concentrator. The stress concentrator may be a notch, groove, channel or similar structure that concentrates stress in the illumination band. The stress concentrator of the illumination band may be notched, scored, indented, pre-weakened or pre-stressed to direct separation of the bone plate 103 from the elongated shaft of the delivery catheter 110 under specific torsional load. The separation area ensures that there are no leaks of filling material from the elongated shaft of the delivery catheter 110 and/or the bone plate 103. The separation area seals the bone plate 103 and removes the elongated shaft of the delivery catheter 110 by making a break at a known or predetermined site (e.g., a separation area). The separation area may be various lengths and up to about an inch long. When torque (twisting) is applied to the delivery catheter 110, the elongated shaft separates from the bone plate 103. The twisting creates a sufficient shear to break the residual filling material and create a clean separation of the plate/shaft interface. The illumination band may be connected to the light source and may be activated by a separate switch. Having a distinct switch to activate the illumination band may help to prevent inadvertent delivery of light from the light source to cure the filling material. The activation of the illumination band seals the bone plate 103 and seals the end of the delivery catheter 110, and ensures that there is a “hard seal” of the filling material at the illumination band allowing no filling material to leak from the bone plate 103 or the delivery catheter 110.
In an embodiment, the bone plate 103 may have a pre-defined shape to fit over a specific bony defect site. The bone plate 103 may be a pad that is round, flat, cylindrical, oval, rectangular or another shape, as long as the bone plate 103 bridges and supports fragments of fractured bone. For example, as depicted in the embodiment of
The bone plate 103 may be formed of a pliable, resilient, conformable, biocompatible, and strong material, including but not limited to urethane, polyethylene terephthalate (PET), nylon elastomer and other similar polymers. In an embodiment, the bone plate 103 is constructed out of a PET nylon aramet or other non-consumable materials. PET is a thermoplastic polymer resin of the polyester family that is used in synthetic fibers. Depending on its processing and thermal history, PET may exist both as an amorphous and as a semi-crystalline material. Semi-crystalline PET has good strength, ductility, stiffness and hardness. Amorphous PET has better ductility, but less stiffness and hardness. PET can be semi-rigid to rigid, depending on its thickness, and is very lightweight. PET is strong and impact-resistant, naturally colorless and transparent and has good resistance to mineral oils, solvents and acids.
The bone plate 103 has an outer surface 122. The outer surface 122 is resilient and puncture resistant. In an embodiment, the outer surface 122 of the bone plate 103 is substantially even and smooth. In an embodiment, the outer surface 122 of the bone plate 103 is not entirely smooth and may have some small bumps or convexity/concavity along the length. In an embodiment, the outer surface 122 of the bone plate 103 may have ribs, ridges, bumps or other shapes to help the bone plate 103 conform to the shape of a bony defect. In an embodiment, the bone plate 103 has a textured surface which provides one or more ridges that allow grabbing all portions of bony defects. In an embodiment, sand blasted surfacing on the outer surface 122 of the bone plate 103 improves the connection and adhesion between the outer surface 122 of the bone plate 103 and the bony defect. The surfacing significantly increases the amount of surface area that comes in contact with the bone resulting in a stronger grip.
The outer surface 122 of the bone plate 103 may be coated with materials such as drugs, bone glue, proteins, growth factors, or other coatings. For example, after a surgical procedure an infection may develop in a patient, requiring the patient to undergo antibiotic treatment. An antibiotic drug may be added to the outer surface 122 of the bone plate 103 to prevent or combat a possible infection. Proteins, such as, for example, the bone morphogenic protein or other growth factors have been shown to induce the formation of cartilage and bone. A growth factor may be added to the outer surface 122 of the bone plate 103 to help induce the formation of new bone. Due to the lack of thermal egress of the filling material in the bone plate 103, the effectiveness and stability of the coating is maintained. In an embodiment, a water soluble glue is applied to the outer surface 122 of the bone plate 103. When the bone plate 103 is expanded and engages a moist bone, the water soluble glue on the outer surface 122 of the bone plate 103 becomes sticky or tacky and acts as a gripping member to increase the conformal bond of the bone plate 103 to the bone. Once the bone plate 103 is inflated, the outer surface 122 of the bone plate 103 grips the bone forming a mechanical bond as well as a chemical bond. These bonds prevent the potential for a bone slippage. The water soluble glue may be cured by any light (e.g., UV not required).
The bone plate 103 of the device 100 typically does not have any valves. One benefit of having no valves is that the bone plate 103 may be inflated or deflated as much as necessary to resemble the contour of the new anatomy of an osteotomy, fracture or bone graft site. Another benefit of the bone plate 103 having no valves is the efficacy and safety of the device 100. Since there is no communication passage of filling material to the body there cannot be any leakage of material because all the material is contained within the bone plate 103. In an embodiment, a permanent seal is created between the bone plate 103 that is both hardened and affixed prior to the delivery catheter 110 being removed. In an embodiment, a permanent seal is created between the bone plate 103 that is hardened, the deliver catheter 119 is removed, and the bone plate 103 is affixed to the bone. The bone plate 103 may have valves, as all of the embodiments are not intended to be limited in this manner.
Once the correct positioning of the bone plate 103 and delivery catheter are determined, the proximal end of the delivery catheter may be attached to a delivery system that contains a filling mixture.
The light source 150 includes a light pipe 152 which terminates in an optical lens 154. Energy emitted from the light pipe 152 is projected through the optical lens 154 and guided into the bone plate 103 of the device 100. The optical lens 154 may be convex, concave or planar. The optical lens 154 is curved to converge or diverge the transmitted energy from the light pipe 152. In an embodiment, the optical lens 154 is made out of a plastic material such as Acrylic (PMMA), Polycarbonate (PC), Polystyrene (PS), or other similar materials known to those in the art such as Cyclic Olefin Copolymer (COC), and Amorphous Polyolefin (Zeonex). In an embodiment, the optical lens 154 is made out of a glass material such as quartz.
The light source 150 is introduced into a side arm of the adapter 115 that engages the proximal end 102 of the delivery catheter 110, as shown in
In an embodiment, the filling material is a light cure adhesive or ultraviolet (UV) adhesive. A benefit of UV curing is that it is a cure-on-demand process and that adhesives may be free of solvents and include environmentally friendly resins that cure in seconds upon exposure to long wave UV light or visible light. Different UV adhesives use photoinitiators sensitive to different ranges of UV and visible light. Being very energetic, UV light can break chemical bonds, making molecules unusually reactive or ionizing them, in general changing their mutual behavior. Visible light, for example, visible blue light, allows materials to be cured between substrates that block UV light but transmits visible light (e.g., plastics). Visible light penetrates through the adhesive to a greater depth. Since the visible light penetrates through the adhesive, curing of the adhesive increases as a greater portion of the electromagnetic spectrum is available as useful energy. Additives may be used with the UV adhesive delivery system, including, but not limited to drugs (for example, antibiotics), proteins (for example, growth factors) or other natural or synthetic additives.
The electromagnetic spectrum is the range of all possible electromagnetic radiation. The electromagnetic spectrum of an object is the frequency range of electromagnetic radiation that the object emits, reflects, or transmits. The electromagnetic spectrum extends from just below the frequencies used for modern radio (at the long-wavelength end) to gamma radiation (at the short-wavelength end), covering wavelengths from thousands of kilometers down to fractions of the size of an atom. In an embodiment, the UV adhesive is a single-component, solvent-free adhesive that will not cure until a UV light engages the adhesive, and when that occurs, the adhesive will cure in seconds to form a complete bond with a shear strength. In an embodiment, the filling material exhibits a shrinkage upon cure of about 2 to about 3 percent.
UV light wavelength ranges from about 1 nm to about 380 nm, and can be subdivided into the following categories: near UV (380-200 nm wavelength; abbreviated NUV), far or vacuum UV (200-10 nm; abbreviated FUV or VUV), and extreme UV (1-31 nm; abbreviated EUV or XUV). Similarly, visible light has a wavelength spectrum of between about 380 to about 780 nm. Those skilled in the art will recognize that some UV adhesives may be activated by UV light, visible light, x-rays, gamma rays, microwaves, radio waves, long waves or any light having a wavelength less than about 1 nm, between about 1 nm and about 380 nm, between about 380 nm and about 780 nm, or greater than 780 nm, as not all embodiments are intended to be limited in that respect.
Using a UV light to cure the filling material assists in holding broken bones in place, filling of the bone plate, and viewing under a C arm imaging system. The filling materials cure in such a way that is sufficient to conform to the contour of a bony defect. More specifically, the ability to inflate, set, adjust, orient bones, and the resulting union of the bone are available prior to hardening the filling material. The introduction of the UV light starts the photoinitiator and the UV adhesive hardens. Once the UV light is introduced, the adhesive inside the bone plate hardens and the adhesives inside are affixed in place. Until the UV light is introduced, the bone placement is not disturbed or rushed as there is no hardening of the adhesives until the light is introduced, the bone plate may be inflated or deflated due to the viscosity of the adhesive. The adhesive may be infused or removed from the bone plate due to the low viscosity of the adhesive. In an embodiment, the viscosity of the filling material has a viscosity of about 1000 cP or less. In an embodiment, the filling material has a viscosity ranging from about 650 cP to about 450 cP. Not all embodiments are intended to be limited in this respect and some embodiments may include filling materials having a viscosity exactly equal to or greater than 1000 cP. In an embodiment, a contrast material may be added to the filling material without significantly increasing the viscosity. Contrast materials include, but are not limited to, barium sulfate, tantalum, or other contrast materials known in the art.
Several epoxies known in the art are suitable for use as filling materials and vary in viscosity, cure times, and hardness (durometer or shore) when fully cured. A durometer of a material indicates the hardness of the material, defined as the material's resistance to permanent indentation. Depending on the amount of resultant support that is necessary for a given bony defect, a specific durometer UV adhesive may be chosen. Alternately, multiple UV adhesives having varying durometers may be chosen for the repair of a bony defect and be within the scope and spirit of the presently disclosed embodiments. The durometer of a material may be altered to achieve either greater rigidity or a more malleable result. The mechanical properties of the epoxies may dictate using methods/measures that are typical for high-strength and high-impact materials including but not limited to, tensile strength and tensile modulus, tensile strength tests, ultimate modulus, Poisson's ratio, hardness measurements like Vickers and Charpy Impact which measures yield strength and toughness.
In an embodiment, the filling material is cured by chemical activation or thermal activation. Chemical activation includes but is not limited to water or other liquids. In an embodiment, the filling material is a drying adhesive which has a polymer dissolved in a solvent such that as the solvent evaporates, the adhesive hardens. In an embodiment, the filling material is a hot or thermoplastic adhesive such that as the adhesive cools, the adhesive hardens.
Some filling materials may require or be enhanced by curing via any means, such as UV or visible light, heat, and/or addition or removal of a chemical or substance, may utilize any outside or internal processes to cure the material, or may not require curing.
In an embodiment, carbon nanotubes (CNTs) are added to the filling material to increase the strength of the material. Carbon nanotubes are an allotrope of carbon that take the form of cylindrical carbon molecules and have novel strength properties. Carbon nanotubes exhibit extraordinary strength. Nanotubes are members of the fullerene structural family, which also includes buckyballs. Whereas buckyballs are spherical in shape, a nanotube is cylindrical with at least one end typically capped with a hemisphere of the buckyball structure. Nanotubes are composed entirely of sp2 bonds, similar to those of graphite. This bonding structure, which is stronger than the sp3 bonds found in diamond, provides the molecules with their unique strength. Nanotubes naturally align themselves into “ropes” held together by Van der Waals forces. Single walled nanotubes or multi-walled nanotubes may be used to strengthen the filling materials.
In an embodiment, a central space may remain in the bone plate 103 which may be filled in order to provide extra strength and support to the fractured bones. An optical rod or similar device may be positioned in the central space and turned on or illuminated. An optical rod or similar device can be made of fiber, silica, quartz, sapphire or similar materials. The end of the optical rod may be cut and remain in the bone plate 103 to provide increased rigidity.
Millions of people sustain trauma to the head and face resulting in complex fractures which, if not correctly diagnosed and treated, may cause permanent functional and cosmetic deformities. In acute trauma cases, the goal of reconstruction is a one-stage repair which has been made possible by the application of craniofacial techniques. Delayed treatment has been replaced by early or immediate surgical treatment and stabilization of small bone fragments augmented by bone grafts and miniplate fixation. These recent advances have allowed surgeons to approach and often reach the goal of restoring preinjury facial appearance and function while at the same time minimizing revisional surgery. Without treatment in a timely manner, many individuals will develop future problems, the severity and consequences of which can be much greater than if the injury had been immediately repaired. Craniofacial surgery encompasses the reconstruction of a broad spectrum of facial deformities including, but not limited to, zygomatic fractures, maxillary fractures, nasoethmoid orbital fractures, internal orbital fractures, mandibular fractures, post-traumatic facial deformities, soft tissue deformities, and facial bone contouring. An implant for fracture fixation must be strong, ductile, adaptable to the bone surface and biocompatible. Fixation system quality includes adequate strength and rigidity, avoiding adverse reactions, interference with bone healing, intracranial migration, visibility and palpability and implant removal operation.
In an embodiment, a separation area is located at the junction between the proximal end 123 of the bone plate 103 and the delivery catheter 110. The separation area may also include an illumination band. When activated, the illumination band causes light to cure the filling material located in the bone plate 103 within the illumination band. The illumination band extends around the delivery catheter 110 and has a stress concentrator. The stress concentrator may be a notch, groove, channel or similar structure that concentrates stress in the illumination band. The stress concentrator of the illumination band may be notched, scored, indented, pre-weakened or pre-stressed to direct separation of the bone plate 103 from the elongated shaft of the delivery catheter 110 under specific torsional load. The separation area ensures that there are no leaks of filling material from the elongated shaft of the delivery catheter 110 and/or the bone plate 103. The separation area seals the bone plate 103 and removes the elongated shaft of the delivery catheter 110 by making a break at a known or predetermined site (e.g., a separation area). The separation area may be various lengths and up to about an inch long. When torque (twisting) is applied to the delivery catheter 110, the elongated shaft separates from the bone plate 103. The twisting creates a sufficient shear to break the residual filling material and create a clean separation of the plate/shaft interface. The illumination band may be connected to the light source and may be activated by a separate switch. Having a distinct switch to activate the illumination band may help to prevent inadvertent delivery of light from the light source to cure the filling material. The activation of the illumination band seals the bone plate 103 and seals the end of the delivery catheter 110, and ensures that there is a “hard seal” of the filling material at the illumination band allowing no filling material to leak from the bone plate 103 or the delivery catheter 110.
The bone plate 103 may be fastened to the bony defect before, after or during a repair procedure. Fasteners 163 are disposed through the apertures 121 and engage the bone plate 103 to secure the bone plate 103 to one or more portions of bone.
A method for adjoining at least two bone fragments includes providing a device for adjoining at least two bone fragments, the device including a conformable bone plate engaged to a delivery catheter having an elongated shaft with a proximal end, a distal end, and a longitudinal axis therebetween, wherein the conformable bone plate has at least one aperture extending from a first surface of the bone plate to a second surface of the bone plate for receiving a fastener to affix the bone plate to the at least two bone fragments; positioning the conformable bone plate over an exterior surface spanning the at least two bone fragments; attaching a delivery system housing at least one filling material to the delivery catheter, wherein the elongated shaft of the delivery catheter has an inner void for passage of the at least one filling material to the conformable bone plate; inserting a light source into the delivery catheter, wherein the elongated shaft of the delivery catheter has an inner lumen for passage of the light source to the conformable bone plate; infusing the at least one filling material through the elongated shaft of the delivery catheter and into the conformable bone plate to expand the conformable bone plate; activating the light source to harden the at least one filling material in the expanded conformable bone plate; releasing the hardened conformable bone plate from the delivery catheter; and affixing the conformable bone plate to the exterior surfaces of the at least two bone fragments to adjoin the bone fragments. In an embodiment, the at least two bone fragments are bones of the face. In an embodiment, the light source is removed from the delivery catheter once the at least one filling material has been hardened.
The bone plates and devices disclosed herein have been discussed in the repair of a craniomaxillofacial bony defect. Those skilled in the art will recognize that the bone plates and devices may be used in a variety of areas, such as bones of the vertebrae and any other fractured bone that required support on its exterior surface so as to hold the disassociated portions in alignment during healing.
All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety. It will be appreciated that various of the above-disclosed and other features and functions, or alternatives thereof, may be desirably combined into many other different systems or applications. Various presently unforeseen or unanticipated alternatives, modifications, variations, or improvements therein may be subsequently made by those skilled in the art which are also intended to be encompassed by the following claims.
This application is a continuation of U.S. application Ser. No. 13/772,947, filed Feb. 21, 2013, which is a continuation of U.S. application Ser. No. 11/964,370, filed on Dec. 26, 2007, now U.S. Pat. No. 8,403,968, the entirety of these applications are hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4280233 | Raab | Jul 1981 | A |
4294251 | Greenwald et al. | Oct 1981 | A |
4313434 | Segal | Feb 1982 | A |
4341691 | Anuta | Jul 1982 | A |
4369772 | Miller | Jan 1983 | A |
4414608 | Furihata | Nov 1983 | A |
4422719 | Orcutt | Dec 1983 | A |
4433898 | Nasiri | Feb 1984 | A |
4462394 | Jacobs | Jul 1984 | A |
4466435 | Murray | Aug 1984 | A |
4562598 | Kranz | Jan 1986 | A |
4686973 | Frisch | Aug 1987 | A |
4697584 | Haynes | Oct 1987 | A |
4735625 | Davidson | Apr 1988 | A |
4870953 | DonMicheal et al. | Oct 1989 | A |
4888024 | Powlan | Dec 1989 | A |
4892550 | Huebsch | Jan 1990 | A |
4904391 | Freeman | Feb 1990 | A |
4961424 | Kubota et al. | Oct 1990 | A |
4963151 | Ducheyne et al. | Oct 1990 | A |
4969888 | Scholten et al. | Nov 1990 | A |
5030093 | Mitnick | Jul 1991 | A |
5049157 | Mittelmeier et al. | Sep 1991 | A |
5085660 | Lin | Feb 1992 | A |
5092899 | Forte | Mar 1992 | A |
5102413 | Poddar | Apr 1992 | A |
5108404 | Scholten et al. | Apr 1992 | A |
5112333 | Fixel | May 1992 | A |
5207669 | Baker et al. | May 1993 | A |
5295733 | LeBegue | Mar 1994 | A |
5295962 | Crocker et al. | Mar 1994 | A |
5303718 | Krajicek | Apr 1994 | A |
5316550 | Forte | May 1994 | A |
5336699 | Cooke et al. | Aug 1994 | A |
5372598 | Luhr et al. | Dec 1994 | A |
5376123 | Klaue et al. | Dec 1994 | A |
5391144 | Sakurai et al. | Feb 1995 | A |
5415654 | Daikuzono | May 1995 | A |
5423850 | Berger | Jun 1995 | A |
5432876 | Appeldorn et al. | Jul 1995 | A |
5443468 | Johnson | Aug 1995 | A |
5462552 | Kiester | Oct 1995 | A |
5480400 | Berger | Jan 1996 | A |
5538514 | Hawkins | Jul 1996 | A |
5548676 | Savage, Jr. | Aug 1996 | A |
5554111 | Morrey et al. | Sep 1996 | A |
5556429 | Felt | Sep 1996 | A |
5571204 | Nies | Nov 1996 | A |
5658310 | Berger | Aug 1997 | A |
5658963 | Qian et al. | Aug 1997 | A |
5705181 | Cooper et al. | Jan 1998 | A |
5707374 | Schmidt | Jan 1998 | A |
5713901 | Tock | Feb 1998 | A |
5795353 | Felt | Aug 1998 | A |
5824087 | Aspden et al. | Oct 1998 | A |
5827289 | Reiley et al. | Oct 1998 | A |
5888220 | Felt et al. | Mar 1999 | A |
5897557 | Chin et al. | Apr 1999 | A |
5908433 | Eager et al. | Jun 1999 | A |
5972015 | Scribner et al. | Oct 1999 | A |
5980075 | Sheaffer | Nov 1999 | A |
5980253 | Oxman et al. | Nov 1999 | A |
5987199 | Zarian et al. | Nov 1999 | A |
5989230 | Frassica | Nov 1999 | A |
5997570 | Ligtenberg et al. | Dec 1999 | A |
6008264 | Ostler | Dec 1999 | A |
6019761 | Gustilo | Feb 2000 | A |
6019774 | Weiss et al. | Feb 2000 | A |
6033411 | Preissman | Mar 2000 | A |
6039762 | McKay | Mar 2000 | A |
6042380 | De Rowe | Mar 2000 | A |
6048346 | Reiley et al. | Apr 2000 | A |
6053917 | Sherman et al. | Apr 2000 | A |
6059789 | Dinger et al. | May 2000 | A |
6066154 | Reiley et al. | May 2000 | A |
6077265 | Werding et al. | Jun 2000 | A |
6079868 | Rydell | Jun 2000 | A |
6103203 | Fischer | Aug 2000 | A |
6110176 | Shapira | Aug 2000 | A |
6121341 | Sawhney et al. | Sep 2000 | A |
6127597 | Beyar et al. | Oct 2000 | A |
6136011 | Stambaugh | Oct 2000 | A |
6140452 | Felt et al. | Oct 2000 | A |
6159236 | Biel | Dec 2000 | A |
6179852 | Strickland et al. | Jan 2001 | B1 |
6195477 | Denuto et al. | Feb 2001 | B1 |
6200134 | Kovac et al. | Mar 2001 | B1 |
6217581 | Tolson | Apr 2001 | B1 |
6223085 | Dann et al. | Apr 2001 | B1 |
6224630 | Bao et al. | May 2001 | B1 |
6235043 | Reiley et al. | May 2001 | B1 |
6241734 | Scribner et al. | Jun 2001 | B1 |
6248110 | Reiley et al. | Jun 2001 | B1 |
6248131 | Felt et al. | Jun 2001 | B1 |
6258089 | Campbell et al. | Jul 2001 | B1 |
6261289 | Levy | Jul 2001 | B1 |
6280456 | Scribner et al. | Aug 2001 | B1 |
6282013 | Ostler et al. | Aug 2001 | B1 |
6290382 | Bourn et al. | Sep 2001 | B1 |
6299597 | Buscemi et al. | Oct 2001 | B1 |
6306177 | Felt et al. | Oct 2001 | B1 |
6319255 | Grundei et al. | Nov 2001 | B1 |
6332894 | Stalcup et al. | Dec 2001 | B1 |
6336914 | Gillespie, III | Jan 2002 | B1 |
6336930 | Stalcup et al. | Jan 2002 | B1 |
6358252 | Shapira | Mar 2002 | B1 |
6387098 | Cole et al. | May 2002 | B1 |
6395007 | Bhatnagar et al. | May 2002 | B1 |
6416531 | Chen | Jul 2002 | B2 |
6416737 | Manolagas et al. | Jul 2002 | B1 |
6419483 | Adam et al. | Jul 2002 | B1 |
6423055 | Farr et al. | Jul 2002 | B1 |
6423083 | Reiley et al. | Jul 2002 | B2 |
6425923 | Stalcup et al. | Jul 2002 | B1 |
6440444 | Boyce et al. | Aug 2002 | B2 |
6443988 | Felt et al. | Sep 2002 | B2 |
6447514 | Stalcup et al. | Sep 2002 | B1 |
6458375 | Gertzman et al. | Oct 2002 | B1 |
6478751 | Krueger et al. | Nov 2002 | B1 |
6482234 | Weber et al. | Nov 2002 | B1 |
6485512 | Cheng | Nov 2002 | B1 |
6494883 | Ferree | Dec 2002 | B1 |
6524251 | Rabiner et al. | Feb 2003 | B2 |
6524313 | Fassier et al. | Feb 2003 | B1 |
6551321 | Burkinshaw et al. | Apr 2003 | B1 |
6551337 | Rabiner et al. | Apr 2003 | B1 |
6565528 | Mueller | May 2003 | B1 |
6579277 | Rabiner et al. | Jun 2003 | B1 |
6579279 | Rabiner et al. | Jun 2003 | B1 |
6620185 | Harvie et al. | Sep 2003 | B1 |
6623505 | Scribner et al. | Sep 2003 | B2 |
6632235 | Weikel et al. | Oct 2003 | B2 |
6648881 | KenKnight et al. | Nov 2003 | B2 |
6652547 | Rabiner et al. | Nov 2003 | B2 |
6652587 | Felt et al. | Nov 2003 | B2 |
6660013 | Rabiner et al. | Dec 2003 | B2 |
6679873 | Rabiner et al. | Jan 2004 | B2 |
6692498 | Niiranen et al. | Feb 2004 | B1 |
6695781 | Rabiner et al. | Feb 2004 | B2 |
6695782 | Rabiner et al. | Feb 2004 | B2 |
6696073 | Boyce et al. | Feb 2004 | B2 |
6716216 | Boucher et al. | Apr 2004 | B1 |
6719773 | Boucher et al. | Apr 2004 | B1 |
6726691 | Osorio et al. | Apr 2004 | B2 |
6730048 | Hare et al. | May 2004 | B1 |
6733451 | Rabiner et al. | May 2004 | B2 |
6733513 | Boyle et al. | May 2004 | B2 |
6740093 | Hochschuler et al. | May 2004 | B2 |
6755862 | Keynan | Jun 2004 | B2 |
6783530 | Levy | Aug 2004 | B1 |
6802835 | Rabiner et al. | Oct 2004 | B2 |
6818018 | Sawhney | Nov 2004 | B1 |
6852095 | Ray | Feb 2005 | B1 |
6866678 | Shenderova et al. | Mar 2005 | B2 |
6869442 | Cheng | Mar 2005 | B2 |
6875212 | Shaolian et al. | Apr 2005 | B2 |
6885246 | Tsutsui et al. | Apr 2005 | B2 |
6887246 | Bhatnagar et al. | May 2005 | B2 |
6887275 | Carchidi et al. | May 2005 | B2 |
6899713 | Shaolian et al. | May 2005 | B2 |
6899719 | Reiley et al. | May 2005 | B2 |
6932843 | Smith et al. | Aug 2005 | B2 |
6964667 | Shaolian et al. | Nov 2005 | B2 |
6979341 | Scribner et al. | Dec 2005 | B2 |
6981981 | Reiley et al. | Jan 2006 | B2 |
7001431 | Bao et al. | Feb 2006 | B2 |
7008433 | Voellmicke et al. | Mar 2006 | B2 |
7048731 | Altshuler et al. | May 2006 | B2 |
7052498 | Levy et al. | May 2006 | B2 |
7077865 | Bao et al. | Jul 2006 | B2 |
7124067 | Ascenzi | Oct 2006 | B2 |
7141061 | Williams et al. | Nov 2006 | B2 |
7144414 | Harvie et al. | Dec 2006 | B2 |
7153305 | Johnson et al. | Dec 2006 | B2 |
7156861 | Scribner et al. | Jan 2007 | B2 |
7156880 | Evans et al. | Jan 2007 | B2 |
7169140 | Kume | Jan 2007 | B1 |
7215863 | Arenella et al. | May 2007 | B1 |
7241303 | Reiss et al. | Jul 2007 | B2 |
7252677 | Burwell et al. | Aug 2007 | B2 |
7258692 | Thelen et al. | Aug 2007 | B2 |
7261720 | Stevens et al. | Aug 2007 | B2 |
7320709 | Felt et al. | Jan 2008 | B2 |
7341601 | Eisermann et al. | Mar 2008 | B2 |
7360542 | Nelson et al. | Apr 2008 | B2 |
7407616 | Melikechi et al. | Aug 2008 | B2 |
7419450 | Ito | Sep 2008 | B2 |
7427295 | Ellman et al. | Sep 2008 | B2 |
7547319 | Segal et al. | Jun 2009 | B2 |
7628800 | Sherman et al. | Dec 2009 | B2 |
7632277 | Woll et al. | Dec 2009 | B2 |
7632291 | Stephens et al. | Dec 2009 | B2 |
7666205 | Weikel et al. | Feb 2010 | B2 |
7722620 | Truckai et al. | May 2010 | B2 |
7740656 | Mensah et al. | Jun 2010 | B2 |
7744555 | DiMauro et al. | Jun 2010 | B2 |
7766965 | Bao et al. | Aug 2010 | B2 |
7771476 | Justis et al. | Aug 2010 | B2 |
7776075 | Bruneau et al. | Aug 2010 | B2 |
7806900 | Rabiner | Oct 2010 | B2 |
7811284 | Rabiner | Oct 2010 | B2 |
7811286 | Medoff | Oct 2010 | B2 |
7811290 | Rabiner | Oct 2010 | B2 |
7842040 | Rabiner et al. | Nov 2010 | B2 |
7850711 | Stone et al. | Dec 2010 | B1 |
7857748 | Williams et al. | Dec 2010 | B2 |
7879041 | Rabiner et al. | Feb 2011 | B2 |
7912539 | Doty et al. | Mar 2011 | B2 |
7947015 | Herweck et al. | May 2011 | B2 |
8034071 | Scribner et al. | Oct 2011 | B2 |
8123807 | Kim et al. | Feb 2012 | B2 |
8210729 | O'Leary et al. | Jul 2012 | B2 |
8211121 | Quinn et al. | Jul 2012 | B1 |
8246628 | Rabiner | Aug 2012 | B2 |
8328402 | O'Leary et al. | Dec 2012 | B2 |
8348956 | Rabiner | Jan 2013 | B2 |
8366711 | Rabiner et al. | Feb 2013 | B2 |
8403968 | Rabiner et al. | Mar 2013 | B2 |
8413664 | Appling | Apr 2013 | B2 |
8512338 | Rabiner et al. | Aug 2013 | B2 |
8574233 | Rabiner et al. | Nov 2013 | B2 |
8668701 | Rabiner et al. | Mar 2014 | B2 |
8672982 | Rabiner et al. | Mar 2014 | B2 |
8684965 | Rabiner et al. | Apr 2014 | B2 |
8708955 | Tilson et al. | Apr 2014 | B2 |
8734460 | Rabiner et al. | May 2014 | B2 |
8764761 | Truckai et al. | Jul 2014 | B2 |
8870965 | Rabiner et al. | Oct 2014 | B2 |
8906030 | Rabiner et al. | Dec 2014 | B2 |
8906031 | Rabiner et al. | Dec 2014 | B2 |
8915966 | Rabiner et al. | Dec 2014 | B2 |
8936382 | O'Leary et al. | Jan 2015 | B2 |
8936644 | Rabiner et al. | Jan 2015 | B2 |
8939977 | DiPoto et al. | Jan 2015 | B2 |
20010011174 | Reiley et al. | Aug 2001 | A1 |
20010044626 | Reiley et al. | Nov 2001 | A1 |
20020082600 | Shaolian et al. | Jun 2002 | A1 |
20020156482 | Scribner et al. | Oct 2002 | A1 |
20020161373 | Osorio et al. | Oct 2002 | A1 |
20020198526 | Shaolian et al. | Dec 2002 | A1 |
20030028210 | Boyle et al. | Feb 2003 | A1 |
20030083642 | Boyd et al. | May 2003 | A1 |
20030105469 | Karmon | Jun 2003 | A1 |
20030114914 | Cheng | Jun 2003 | A1 |
20030156431 | Gozum et al. | Aug 2003 | A1 |
20030199850 | Chavez et al. | Oct 2003 | A1 |
20030212426 | Olson et al. | Nov 2003 | A1 |
20030229372 | Reiley et al. | Dec 2003 | A1 |
20040006341 | Shaolian et al. | Jan 2004 | A1 |
20040024388 | Altshuler | Feb 2004 | A1 |
20040034434 | Evans et al. | Feb 2004 | A1 |
20040059333 | Carl et al. | Mar 2004 | A1 |
20040059417 | Smith et al. | Mar 2004 | A1 |
20040092948 | Stevens et al. | May 2004 | A1 |
20040098015 | Weikel et al. | May 2004 | A1 |
20040117025 | Reindel | Jun 2004 | A1 |
20040133280 | Trieu | Jul 2004 | A1 |
20040167561 | Boucher et al. | Aug 2004 | A1 |
20040167625 | Beyar et al. | Aug 2004 | A1 |
20040225296 | Reiss et al. | Nov 2004 | A1 |
20040228142 | Takada et al. | Nov 2004 | A1 |
20040230309 | Di Mauro et al. | Nov 2004 | A1 |
20040247641 | Felt et al. | Dec 2004 | A1 |
20050010231 | Myers | Jan 2005 | A1 |
20050015140 | deBeer | Jan 2005 | A1 |
20050015148 | Jansen et al. | Jan 2005 | A1 |
20050018989 | Shimizu et al. | Jan 2005 | A1 |
20050043733 | Eisermann et al. | Feb 2005 | A1 |
20050043808 | Felt et al. | Feb 2005 | A1 |
20050049691 | Mericle et al. | Mar 2005 | A1 |
20050090901 | Studer | Apr 2005 | A1 |
20050119662 | Reiley et al. | Jun 2005 | A1 |
20050142315 | DeSimone et al. | Jun 2005 | A1 |
20050149022 | Shaolian et al. | Jul 2005 | A1 |
20050159749 | Levy et al. | Jul 2005 | A1 |
20050171604 | Michalow | Aug 2005 | A1 |
20050192671 | Bao et al. | Sep 2005 | A1 |
20050197711 | Cachia | Sep 2005 | A1 |
20050228260 | Burwell et al. | Oct 2005 | A1 |
20050234453 | Shaolian et al. | Oct 2005 | A1 |
20050251140 | Shaolian et al. | Nov 2005 | A1 |
20050284485 | Nelson et al. | Dec 2005 | A9 |
20060009550 | Messersmith et al. | Jan 2006 | A1 |
20060015105 | Warren et al. | Jan 2006 | A1 |
20060036253 | Leroux et al. | Feb 2006 | A1 |
20060084985 | Kim et al. | Apr 2006 | A1 |
20060100547 | Rabiner et al. | May 2006 | A1 |
20060100635 | Reiley et al. | May 2006 | A1 |
20060100706 | Shadduck et al. | May 2006 | A1 |
20060111726 | Felt et al. | May 2006 | A1 |
20060122625 | Truckai et al. | Jun 2006 | A1 |
20060142747 | Appling | Jun 2006 | A1 |
20060155296 | Richter | Jul 2006 | A1 |
20060173464 | Ellman et al. | Aug 2006 | A1 |
20060183811 | Melikechi et al. | Aug 2006 | A1 |
20060184246 | Zwirkoski | Aug 2006 | A1 |
20060195165 | Gertner et al. | Aug 2006 | A1 |
20060217747 | Ferree | Sep 2006 | A1 |
20060229617 | Meller et al. | Oct 2006 | A1 |
20060247787 | Rydell et al. | Nov 2006 | A1 |
20060253102 | Nance et al. | Nov 2006 | A1 |
20060253200 | Bao et al. | Nov 2006 | A1 |
20060258981 | Eidenschink | Nov 2006 | A1 |
20060264950 | Nelson et al. | Nov 2006 | A1 |
20060264951 | Nelson et al. | Nov 2006 | A1 |
20060264952 | Nelson et al. | Nov 2006 | A1 |
20060265077 | Zwirkoski | Nov 2006 | A1 |
20060271061 | Beyar et al. | Nov 2006 | A1 |
20060276793 | Berry | Dec 2006 | A1 |
20060276819 | Osorio et al. | Dec 2006 | A1 |
20060282169 | Felt et al. | Dec 2006 | A1 |
20060287730 | Segal et al. | Dec 2006 | A1 |
20070027547 | Rydell et al. | Feb 2007 | A1 |
20070067032 | Felt et al. | Mar 2007 | A1 |
20070087031 | Ashman et al. | Apr 2007 | A1 |
20070100327 | Smith | May 2007 | A1 |
20070104416 | Shimizu et al. | May 2007 | A1 |
20070118143 | Ralph et al. | May 2007 | A1 |
20070123876 | Czartoski et al. | May 2007 | A1 |
20070123877 | Goldin et al. | May 2007 | A1 |
20070123878 | Shaver et al. | May 2007 | A1 |
20070161991 | Altarac et al. | Jul 2007 | A1 |
20070198023 | Sand et al. | Aug 2007 | A1 |
20070225705 | Osorio et al. | Sep 2007 | A1 |
20070233146 | Henniges et al. | Oct 2007 | A1 |
20070239148 | Scheller | Oct 2007 | A1 |
20070255287 | Rabiner | Nov 2007 | A1 |
20080015500 | Herweck et al. | Jan 2008 | A1 |
20080019657 | Maitland et al. | Jan 2008 | A1 |
20080021474 | Bonutti et al. | Jan 2008 | A1 |
20080039854 | Rabiner | Feb 2008 | A1 |
20080080205 | Forrester et al. | Apr 2008 | A1 |
20080103505 | Fransen | May 2008 | A1 |
20080125784 | Rabiner et al. | May 2008 | A1 |
20080154266 | Protopsaltis et al. | Jun 2008 | A1 |
20080154368 | Justis | Jun 2008 | A1 |
20080154373 | Protopsaltis et al. | Jun 2008 | A1 |
20080183122 | Fisher et al. | Jul 2008 | A1 |
20080188858 | Luzzi et al. | Aug 2008 | A1 |
20080234820 | Felt et al. | Sep 2008 | A1 |
20080249529 | Zarda et al. | Oct 2008 | A1 |
20080255560 | Myers et al. | Oct 2008 | A1 |
20080269750 | Justin | Oct 2008 | A1 |
20080287951 | Stoneburger et al. | Nov 2008 | A1 |
20090018524 | Greenhalgh et al. | Jan 2009 | A1 |
20090024166 | Carl et al. | Jan 2009 | A1 |
20090048629 | Rabiner | Feb 2009 | A1 |
20090054900 | Rabiner et al. | Feb 2009 | A1 |
20090093887 | Walter et al. | Apr 2009 | A1 |
20090112196 | Rabiner et al. | Apr 2009 | A1 |
20090118833 | Hudgins et al. | May 2009 | A1 |
20090171265 | Doty et al. | Jul 2009 | A1 |
20090171358 | Chang et al. | Jul 2009 | A1 |
20090177204 | Colleran et al. | Jul 2009 | A1 |
20090182336 | Brenzel et al. | Jul 2009 | A1 |
20090187192 | Rabiner et al. | Jul 2009 | A1 |
20090216232 | Buford, III et al. | Aug 2009 | A1 |
20090228007 | Justin et al. | Sep 2009 | A1 |
20090254064 | Boatman | Oct 2009 | A1 |
20090287309 | Walch et al. | Nov 2009 | A1 |
20090306589 | Tilson et al. | Dec 2009 | A1 |
20100234958 | Linares | Sep 2010 | A1 |
20100241178 | Tilson et al. | Sep 2010 | A1 |
20100249942 | Goswami et al. | Sep 2010 | A1 |
20100256641 | Rabiner et al. | Oct 2010 | A1 |
20100262069 | Rabiner et al. | Oct 2010 | A1 |
20100262188 | Rabiner et al. | Oct 2010 | A1 |
20100265733 | O'Leary et al. | Oct 2010 | A1 |
20100318087 | Scribner et al. | Dec 2010 | A1 |
20100331850 | Rabiner | Dec 2010 | A1 |
20110004213 | Rabiner et al. | Jan 2011 | A1 |
20110009871 | Rabiner | Jan 2011 | A1 |
20110029093 | Bojarski et al. | Feb 2011 | A1 |
20110046746 | Rabiner et al. | Feb 2011 | A1 |
20110082504 | Singhatt et al. | Apr 2011 | A1 |
20110098713 | Rabiner et al. | Apr 2011 | A1 |
20110110114 | Papac et al. | May 2011 | A1 |
20110112588 | Linderman et al. | May 2011 | A1 |
20110118740 | Rabiner et al. | May 2011 | A1 |
20110137317 | O'Halloran et al. | Jun 2011 | A1 |
20110160870 | Baumgartner et al. | Jun 2011 | A1 |
20110166306 | Stansbury et al. | Jul 2011 | A1 |
20110313356 | Rabiner et al. | Dec 2011 | A1 |
20120029102 | Rose et al. | Feb 2012 | A1 |
20120041557 | Frigg | Feb 2012 | A1 |
20120165941 | Rabiner et al. | Jun 2012 | A1 |
20120259375 | Druma et al. | Oct 2012 | A1 |
20120262939 | O'Leary et al. | Oct 2012 | A1 |
20120289968 | Rabiner | Nov 2012 | A1 |
20120316652 | Renganath et al. | Dec 2012 | A1 |
20130003406 | O'Leary et al. | Jan 2013 | A1 |
20130006304 | Rabiner et al. | Jan 2013 | A1 |
20130012998 | Altarac et al. | Jan 2013 | A1 |
20130013008 | Rabiner et al. | Jan 2013 | A1 |
20130013009 | Colleran et al. | Jan 2013 | A1 |
20130013010 | Rabiner et al. | Jan 2013 | A1 |
20130018482 | Meridew et al. | Jan 2013 | A1 |
20130023876 | Rabiner et al. | Jan 2013 | A1 |
20130023877 | Rabiner et al. | Jan 2013 | A1 |
20130023886 | Rabiner et al. | Jan 2013 | A1 |
20130041472 | Rabiner et al. | Feb 2013 | A1 |
20130046390 | Rabiner et al. | Feb 2013 | A1 |
20130066326 | Rabiner et al. | Mar 2013 | A1 |
20130158607 | Rabiner et al. | Jun 2013 | A1 |
20130184715 | Rabiner et al. | Jul 2013 | A1 |
20140018806 | DiPoto et al. | Jan 2014 | A1 |
20140142581 | Rabiner et al. | May 2014 | A1 |
20140148813 | Rabiner et al. | May 2014 | A1 |
20140163453 | Rabiner et al. | Jun 2014 | A1 |
20140180288 | Rabiner et al. | Jun 2014 | A1 |
Number | Date | Country |
---|---|---|
40 28 466 | Mar 1992 | DE |
0 709 698 | May 1996 | EP |
2001-527437 | Dec 2001 | JP |
2004-526525 | Sep 2002 | JP |
2005-511143 | Apr 2005 | JP |
2006-212425 | Aug 2006 | JP |
9001858 | Mar 1992 | NL |
WO 9838918 | Sep 1998 | WO |
WO9943266 | Sep 1999 | WO |
WO 0243628 | Jun 2002 | WO |
WO 03047472 | Jun 2003 | WO |
WO 2004045393 | Jun 2004 | WO |
WO 2004058045 | Jul 2004 | WO |
WO 2004073563 | Sep 2004 | WO |
WO 2004112661 | Dec 2004 | WO |
WO 2005112804 | Dec 2005 | WO |
WO 2006016807 | Feb 2006 | WO |
WO2007002251 | Jan 2007 | WO |
WO 2007059259 | May 2007 | WO |
WO 2007075375 | Jul 2007 | WO |
WO 2007127255 | Nov 2007 | WO |
WO 2007127260 | Nov 2007 | WO |
WO 2008039811 | Apr 2008 | WO |
WO 2008063265 | May 2008 | WO |
WO 2009059090 | May 2009 | WO |
WO 2009064847 | May 2009 | WO |
WO 2009082688 | Jul 2009 | WO |
WO2009088927 | Jul 2009 | WO |
WO 2009131999 | Oct 2009 | WO |
WO 2010050965 | May 2010 | WO |
WO 2010118158 | Oct 2010 | WO |
WO 2011060062 | May 2011 | WO |
WO 2011071567 | Jun 2011 | WO |
WO2011162910 | Dec 2011 | WO |
WO2012051312 | Apr 2012 | WO |
WO 2012088432 | Jun 2012 | WO |
WO 2013013069 | Jan 2013 | WO |
WO 2013013071 | Jan 2013 | WO |
WO 2013013072 | Jan 2013 | WO |
WO 2013059609 | Apr 2013 | WO |
WO2014011669 | Jan 2014 | WO |
WO 2014100427 | Jun 2014 | WO |
Entry |
---|
PCT International Search Report based on PCT/US13/049773 dated Oct. 1, 2013. |
USPTO Office Action in U.S. Appl. No. 12/756,014 mailed Oct. 7, 2014. |
USPTO Office Action in U.S. Appl. No. 13/553,450 mailed Oct. 24, 2014. |
USPTO Office Action in U.S. Appl. No. 13/335,110 mailed Oct. 24, 2014. |
USPTO Office Action in U.S. Appl. No. 13/553,247 mailed Dec. 5, 2014. |
USPTO Office Action in U.S. Appl. No. 13/553,051 mailed Dec. 23, 2014. |
USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Jan. 14, 2015. |
USPTO Office Action in U.S. Appl. No. 13/617,557 mailed Jan. 15, 2015. |
Jovanovic et al., “Fixion Nails for Humeral Fractures, Injury”, Int. J. Care Injured, vol. 35, Issue 11, pp. 1140-1142, Nov. 2004. |
Maruyama et al., “Metacarpal Fracture Fixation with Absorbable Polyglycolide Rods and Stainless Steel K Wires: A Biomechanical Comparison”, Journal of Biomedical Materials Research (Applied Biomaterials), vol. 33, Issue 1, pp. 9-12, Apr. 1996. |
Waris et al., “Bioabsorbable Miniplating Versus Metallic Fixation for Metacarpal Fractures”, Clinical Orthopaedics and Related Research, No. 410, pp. 310-319, May 2003. |
Waris et al., “Self-Reinforced Bioabsorbable Versus Metallic Fixation Systems for Metacarpal and Phalangeal Fractures: A Biomechanical Study”, The Journal of Hand Surgery, vol. 27A, No. 5, pp. 902-909, Sep. 2002. |
PCT International Search Report based on PCT/US07/20402 dated Apr. 1, 2008. |
PCT International Search Report based on PCT/US07/10050 dated Apr. 17, 2008. |
PCT International Search Report based on PCT/US07/10038 dated Aug. 27, 2008. |
PCT International Search Report based on PCT/US08/81929 dated Jan. 12, 2009. |
PCT International Search Report based on PCT/US08/81924 dated Feb. 9, 2009. |
PCT International Search Report based on PCT/US08/87630 dated Feb. 24, 2009. |
PCT International Search Report based on PCT/US10/30275 dated Aug. 11, 2010. |
PCT International Search Report based on PCT/US10/56219 dated Jan. 20, 2011. |
PCT International Search Report based on PCT/US10/46003 dated May 24, 2011. |
PCT International Search Report based on PCT/US11/38389 dated Sep. 22, 2011. |
PCT International Search Report based on PCT/US11/66871 dated May 1, 2012. |
USPTO Office Action in U.S. Appl. No. 11/789,906 mailed Apr. 29, 2009. |
USPTO Office Action in U.S. Appl. No. 11/789,906 mailed Mar. 11, 2010. |
USPTO Office Action in U.S. Appl. No. 11/789,906 mailed Apr. 30, 2010. |
USPTO Office Action in U.S. Appl. No. 11/789,907 mailed May 11, 2010. |
USPTO Office Action in U.S. Appl. No. 11/903,123 mailed Jul. 1, 2010. |
USPTO Office Action in U.S. Appl. No. 12/262,411 mailed Sep. 1, 2010. |
USPTO Office Action in U.S. Appl. No. 11/964,370 mailed Dec. 9, 2010. |
USPTO Office Action in U.S. Appl. No. 11/964,370 mailed Apr. 28, 2011. |
USPTO Office Action in U.S. Appl. No. 11/964,370 mailed Sep. 23, 2011. |
USPTO Office Action in U.S. Appl. No. 12/858,924 mailed Oct. 24, 2011. |
USPTO Office Action in U.S. Appl. No. 12/755,784 mailed Dec. 23, 2011. |
USPTO Office Action in U.S. Appl. No. 12/886,288 mailed Dec. 27, 2011. |
USPTO Office Action in U.S. Appl. No. 12/875,460 mailed Mar. 8, 2012. |
USPTO Office Action in U.S. Appl. No. 11/964,370 mailed Mar. 16, 2012. |
USPTO Office Action in U.S. Appl. No. 12/858,924 mailed Apr. 4, 2012. |
USPTO Office Action in U.S. Appl. No. 12/756,014 mailed May 11, 2012. |
USPTO Office Action in U.S. Appl. No. 12/262,370 mailed May 29, 2012. |
USPTO Office Action in U.S. Appl. No. 12/943,544 mailed Jun. 8, 2012. |
USPTO Office Action in U.S. Appl. No. 12/886,288 mailed Jun. 26, 2012. |
USPTO Office Action in U.S. Appl. No. 11/964,370 mailed Jul. 6, 2012. |
Extended European Search Report based on EP 07 75 6022 dated Jul. 19, 2012. |
Extended European Search Report based on EP 07 75 6016 dated Jul. 18, 2012. |
USPTO Office Action in U.S. Appl. No. 12/755,784 mailed Aug. 1, 2012. |
USPTO Office Action in U.S. Appl. No. 12/858,924 mailed Aug. 2, 2012. |
USPTO Office Action in U.S. Appl. No. 12/886,288 mailed Aug. 15, 2012. |
PCT International Search Report based on PCT/US12/47447 dated Oct. 2, 2012. |
PCT International Search Report based on PCT/US12/47446 dated Oct. 15, 2012. |
PCT International Search Report based on PCT/US12/47444 dated Oct. 18, 2012. |
USPTO Office Action in U.S. Appl. No. 12/756,014 mailed Oct. 25, 2012. |
USPTO Office Action in U.S. Appl. No. 12/859,680 mailed Nov. 9, 2012. |
USPTO Office Action in U.S. Appl. No. 12/943,544 mailed Dec. 3, 2012. |
USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Dec. 14, 2012. |
International Search Report and Written Opinion for PCT/US2012/061047 mailed Jan. 7, 2013. |
USPTO Office Action in U.S. Appl. No. 12/859,680 mailed Jan. 17, 2013. |
USPTO Office Action in U.S. Appl. No. 12/756,014 mailed Jan. 22, 2013. |
USPTO Office Action in U.S. Appl. No. 13/088,916 mailed Jan. 23, 2013. |
USPTO Office Action in U.S. Appl. No. 13/617,557 mailed Feb. 4, 2013. |
USPTO Office Action in U.S. Appl. No. 12/755,784 mailed Mar. 13, 2013. |
USPTO Office Action in U.S. Appl. No. 13/616,416 mailed Mar. 25, 2013. |
USPTO Office Action in U.S. Appl. No. 13/561,249 mailed Apr. 23, 2013. |
USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Apr. 26, 2013. |
USPTO Office Action in U.S. Appl. No. 13/088,916 mailed May 13, 2013. |
Supplemental European Search Report based on EP 08 87 7881 dated May 15, 2013. |
USPTO Office Action in U.S. Appl. No. 13/772,947 mailed Jun. 19, 2013. |
USPTO Office Action in U.S. Appl. No. 12/859,680 mailed Jul. 9, 2013. |
USPTO Office Action in U.S. Appl. No. 13/561,249 mailed Sep. 16, 2013. |
USPTO Office Action in U.S. Appl. No. 13/088,916 mailed Sep. 17, 2013. |
USPTO Office Action in U.S. Appl. No. 12/943,544 mailed Sep. 25, 2013. |
USPTO Office Action in U.S. Appl. No. 13/617,557 mailed Oct. 9, 2013. |
Extended European Search Report based on EP 10 76 2390 dated Oct. 30, 2013. |
USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Nov. 21, 2013. |
USPTO Office Action in U.S. Appl. No. 12/983,496 mailed Feb. 5, 2014. |
USPTO Office Action in U.S. Appl. No. 12/756,014 mailed Feb. 13, 2014. |
USPTO Office Action in U.S. Appl. No. 13/617,181 mailed Feb. 25, 2014. |
PCT International Search Report based on PCT/US13/076598 dated Mar. 19, 2014. |
USPTO Office Action in U.S. Appl. No. 13/655,808 mailed Mar. 27, 2014. |
USPTO Office Action in U.S. Appl. No. 13/553,247 mailed May 7, 2014. |
Extended European Search Report based on EP 14156473 dated May 13, 2014. |
USPTO Office Action in U.S. Appl. No. 13/800,518 mailed Jun. 10, 2014. |
USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Jun. 26, 2014. |
USPTO Office Action in U.S. Appl. No. 13/617,557 mailed Jun. 27, 2014. |
USPTO Office Action in U.S. Appl. No. 13/335,110 mailed Jul. 31, 2014. |
USPTO Office Action in U.S. Appl. No. 13/616,781 mailed Aug. 26, 2014. |
USPTO Office Action in U.S. Appl. No. 13/730,521 mailed Sep. 8, 2014. |
Number | Date | Country | |
---|---|---|---|
20140135847 A1 | May 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13772947 | Feb 2013 | US |
Child | 14163027 | US | |
Parent | 11964370 | Dec 2007 | US |
Child | 13772947 | US |